Capital International Inc. CA Raises Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Capital International Inc. CA grew its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 193.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,493 shares of the biotechnology company’s stock after buying an additional 14,822 shares during the quarter. Capital International Inc. CA’s holdings in Sarepta Therapeutics were worth $2,735,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its stake in shares of Sarepta Therapeutics by 10.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 310,810 shares of the biotechnology company’s stock valued at $37,791,000 after acquiring an additional 30,615 shares during the period. Capital International Ltd. CA boosted its stake in shares of Sarepta Therapeutics by 31.0% during the fourth quarter. Capital International Ltd. CA now owns 18,430 shares of the biotechnology company’s stock valued at $2,241,000 after purchasing an additional 4,357 shares in the last quarter. Capital Group Investment Management PTE. LTD. grew its stake in Sarepta Therapeutics by 30.2% in the fourth quarter. Capital Group Investment Management PTE. LTD. now owns 3,689 shares of the biotechnology company’s stock valued at $449,000 after purchasing an additional 856 shares during the last quarter. Capital Group Private Client Services Inc. grew its position in shares of Sarepta Therapeutics by 95.8% in the 4th quarter. Capital Group Private Client Services Inc. now owns 119,218 shares of the biotechnology company’s stock worth $14,496,000 after buying an additional 58,335 shares during the last quarter. Finally, Capital International Investors grew its holdings in Sarepta Therapeutics by 38.9% in the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock worth $1,057,482,000 after purchasing an additional 2,437,855 shares during the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $53.79 on Monday. The stock has a market capitalization of $5.22 billion, a PE ratio of 43.03 and a beta of 0.93. The firm has a 50 day moving average of $82.21 and a two-hundred day moving average of $107.70. Sarepta Therapeutics, Inc. has a 52 week low of $48.01 and a 52 week high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 7.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft dropped their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a research note on Wednesday, March 19th. Scotiabank reduced their price objective on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research note on Thursday, March 20th. Wells Fargo & Company initiated coverage on shares of Sarepta Therapeutics in a research note on Friday, April 11th. They issued an “overweight” rating and a $115.00 target price for the company. Needham & Company LLC lowered their price target on Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating on the stock in a research report on Thursday, April 3rd. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a report on Wednesday, April 16th. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $161.83.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.